aTYR PHARMA Director Departs, New Director Appointed
Ticker: ATYR · Form: 8-K · Filed: Dec 12, 2024 · CIK: 1339970
| Field | Detail |
|---|---|
| Company | Atyr Pharma Inc (ATYR) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation
TL;DR
Board shakeup at aTYR PHARMA: Director out, new one in, plus new pay plans.
AI Summary
On December 10, 2024, aTYR PHARMA, INC. reported the departure of Director Dr. Steven M. Altschuler and the appointment of Dr. David J. Earp as a new director. The company also announced a new compensatory arrangement for its officers.
Why It Matters
Changes in the board of directors can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing primarily concerns routine board changes and compensatory arrangements, with no immediate financial distress or significant operational shifts indicated.
Key Players & Entities
- aTYR PHARMA, INC. (company) — Registrant
- Dr. Steven M. Altschuler (person) — Departing Director
- Dr. David J. Earp (person) — Newly Appointed Director
- December 10, 2024 (date) — Date of earliest event reported
FAQ
Who has departed from the aTYR PHARMA, INC. board of directors?
Dr. Steven M. Altschuler has departed from the board of directors of aTYR PHARMA, INC.
Who has been appointed as a new director to aTYR PHARMA, INC.'s board?
Dr. David J. Earp has been appointed as a new director to aTYR PHARMA, INC.'s board.
What is the effective date of the events reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on December 10, 2024.
What other significant item is reported in this 8-K filing besides director changes?
The filing also reports on compensatory arrangements of certain officers.
In which state is aTYR PHARMA, INC. incorporated?
aTYR PHARMA, INC. is incorporated in Delaware.
Filing Stats: 664 words · 3 min read · ~2 pages · Grade level 12.7 · Accepted 2024-12-12 16:05:06
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ATYR The Nasdaq Capital M
Filing Documents
- atyr-20241210.htm (8-K) — 52KB
- atyr-ex99_1.htm (EX-99.1) — 13KB
- 0000950170-24-135766.txt ( ) — 182KB
- atyr-20241210.xsd (EX-101.SCH) — 26KB
- atyr-20241210_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Non-Employee Director Compensation Policy, as amended 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ATYR PHARMA, INC. By: /s/ Jill M. Broadfoot Jill M. Broadfoot Chief Financial Officer Date: December 12, 2024 3